Search

Your search keyword '"Schlegelberger, B. (Brigitte)"' showing total 5 results
Start Over Author "Schlegelberger, B. (Brigitte)"
5 results on '"Schlegelberger, B. (Brigitte)"'

1. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: A subset analysis from the MDS-004 study

Author

Giagounidis, A. (Aristoteles), Mufti, G.J. (Ghulam), Mittelman, M. (Moshe), Sanz, G. (Guillermo), Platzbecker, U. (Uwe), Muus, P. (P.), Selleslag, D., Beyne-Rauzy, O. (Odile), Boekhorst, P.A.W. (Peter) te, Cañizo, C. (Consuelo) del, Guerci-Bresler, A. (Agnes), Nilsson, L. (Lars), Lübbert, M. (Michael), Quesnel, B. (Bruno), Ganser, A. (Arnold), Bowen, D. (David), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Fu, T. (Tommy), Benettaib, B. (Bouchra), Hellström-Lindberg, E. (Eva), Fenaux, P. (Pierre), Giagounidis, A. (Aristoteles), Mufti, G.J. (Ghulam), Mittelman, M. (Moshe), Sanz, G. (Guillermo), Platzbecker, U. (Uwe), Muus, P. (P.), Selleslag, D., Beyne-Rauzy, O. (Odile), Boekhorst, P.A.W. (Peter) te, Cañizo, C. (Consuelo) del, Guerci-Bresler, A. (Agnes), Nilsson, L. (Lars), Lübbert, M. (Michael), Quesnel, B. (Bruno), Ganser, A. (Arnold), Bowen, D. (David), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Fu, T. (Tommy), Benettaib, B. (Bouchra), Hellström-Lindberg, E. (Eva), and Fenaux, P. (Pierre)

Abstract

Objective: A subset analysis of the randomised, phase 3, MDS-004 study to evaluate outcomes in patients with International Prognostic Scoring System (IPSS)-defined Low-/Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) with isolated del(5q). Methods: Patients received lenalidomide 10 mg/d (days 1-21; n = 47) or 5 mg/d (days 1-28; n = 43) on 28-d cycles or placebo (n = 45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over to lenalidomide 5 or 10 mg at 16 wk, respectively. Results: Rates of red blood cell-transfusion independence (RBC-TI) ≥182 d were higher in the lenalidomide 10 mg (57.4%; P < 0.0001) and 5 mg (37.2%; P = 0.0001) groups vs. placebo (2.2%). Cytogenetic response rates (major + minor responses) were 56.8% (P < 0.0001), 23.1% (P = 0.0299) and 0%, respectively. Two-year cumulative risk of acute myeloid leukaemia progression was 12.6%, 17.4% and 16.7% in the lenalidomide 10 mg, 5 mg, and placebo groups, respectively. In a 6-month landmark analysis, overall survival was longer in lenalidomide-treated patients with RBC-TI ≥182 d vs. non-responders (P = 0.0072). The most common grade 3-4 adverse event was myelosuppression. Conclusions: These data support the clinical benefits and acceptable safety profile of lenalidomide in transfusion-dependent patients with IPSS-defined Low-/Int-1-risk MDS with isolated del(5q).

Published
2014
Full Text
View/download PDF

2. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: A subset analysis from the MDS-004 study

Author

Giagounidis, A. (Aristoteles), Mufti, G.J. (Ghulam), Mittelman, M. (Moshe), Sanz, G. (Guillermo), Platzbecker, U. (Uwe), Muus, P. (P.), Selleslag, D., Beyne-Rauzy, O. (Odile), Boekhorst, P.A.W. (Peter) te, Cañizo, C. (Consuelo) del, Guerci-Bresler, A. (Agnes), Nilsson, L. (Lars), Lübbert, M. (Michael), Quesnel, B. (Bruno), Ganser, A. (Arnold), Bowen, D. (David), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Fu, T. (Tommy), Benettaib, B. (Bouchra), Hellström-Lindberg, E. (Eva), Fenaux, P. (Pierre), Giagounidis, A. (Aristoteles), Mufti, G.J. (Ghulam), Mittelman, M. (Moshe), Sanz, G. (Guillermo), Platzbecker, U. (Uwe), Muus, P. (P.), Selleslag, D., Beyne-Rauzy, O. (Odile), Boekhorst, P.A.W. (Peter) te, Cañizo, C. (Consuelo) del, Guerci-Bresler, A. (Agnes), Nilsson, L. (Lars), Lübbert, M. (Michael), Quesnel, B. (Bruno), Ganser, A. (Arnold), Bowen, D. (David), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Fu, T. (Tommy), Benettaib, B. (Bouchra), Hellström-Lindberg, E. (Eva), and Fenaux, P. (Pierre)

Abstract

Objective: A subset analysis of the randomised, phase 3, MDS-004 study to evaluate outcomes in patients with International Prognostic Scoring System (IPSS)-defined Low-/Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) with isolated del(5q). Methods: Patients received lenalidomide 10 mg/d (days 1-21; n = 47) or 5 mg/d (days 1-28; n = 43) on 28-d cycles or placebo (n = 45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over to lenalidomide 5 or 10 mg at 16 wk, respectively. Results: Rates of red blood cell-transfusion independence (RBC-TI) ≥182 d were higher in the lenalidomide 10 mg (57.4%; P < 0.0001) and 5 mg (37.2%; P = 0.0001) groups vs. placebo (2.2%). Cytogenetic response rates (major + minor responses) were 56.8% (P < 0.0001), 23.1% (P = 0.0299) and 0%, respectively. Two-year cumulative risk of acute myeloid leukaemia progression was 12.6%, 17.4% and 16.7% in the lenalidomide 10 mg, 5 mg, and placebo groups, respectively. In a 6-month landmark analysis, overall survival was longer in lenalidomide-treated patients with RBC-TI ≥182 d vs. non-responders (P = 0.0072). The most common grade 3-4 adverse event was myelosuppression. Conclusions: These data support the clinical benefits and acceptable safety profile of lenalidomide in transfusion-dependent patients with IPSS-defined Low-/Int-1-risk MDS with isolated del(5q).

Published
2014
Full Text
View/download PDF

3. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: A study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

Author

Gröschel, S. (Stefan), Schlenk, R.F. (Richard), Engelmann, J., Rockova, V. (Veronika), Teleanu, V. (Veronica), Kühn, M.W.M. (Michael), Eiwen, K. (Karina), Erpelinck, C.A.J. (Claudia), Havermans, M. (Marije), Lübbert, M. (Michael), Germing, U. (Ulrich), Schmidt-Wolf, I.G.H., Beverloo, H.B. (Berna), Schuurhuis, G.J. (Gerrit Jan), Ossenkoppele, G.J. (Gert), Schlegelberger, B. (Brigitte), Verdonck, L.F. (Leo), Vellenga, E. (Edo), Verhoef, G.E.G. (Gregor), Vandenberghe, P. (Peter), Pabst, T. (Thomas), Bargetzi, M. (Mario), Krauter, J., Ganser, A. (Arnold), Valk, P.J.M. (Peter), Löwenberg, B. (Bob), Döhner, K. (Konstanze), Döhner, H. (Hartmut), Delwel, H.R. (Ruud), Gröschel, S. (Stefan), Schlenk, R.F. (Richard), Engelmann, J., Rockova, V. (Veronika), Teleanu, V. (Veronica), Kühn, M.W.M. (Michael), Eiwen, K. (Karina), Erpelinck, C.A.J. (Claudia), Havermans, M. (Marije), Lübbert, M. (Michael), Germing, U. (Ulrich), Schmidt-Wolf, I.G.H., Beverloo, H.B. (Berna), Schuurhuis, G.J. (Gerrit Jan), Ossenkoppele, G.J. (Gert), Schlegelberger, B. (Brigitte), Verdonck, L.F. (Leo), Vellenga, E. (Edo), Verhoef, G.E.G. (Gregor), Vandenberghe, P. (Peter), Pabst, T. (Thomas), Bargetzi, M. (Mario), Krauter, J., Ganser, A. (Arnold), Valk, P.J.M. (Peter), Löwenberg, B. (Bob), Döhner, K. (Konstanze), Döhner, H. (Hartmut), and Delwel, H.R. (Ruud)

Abstract

Purpose: To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. Patients and Methods: We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgi

Published
2013
Full Text
View/download PDF

4. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML

Author

Hirabayashi, S. (Shinsuke), Flotho, C. (Christian), Moetter, J. (Jessica), Heuser, M. (Michael), Hasle, H. (Henrik), Gruhn, B. (Bernd), Klingebiel, T. (Thomas), Thol, F. (Felicitas), Schlegelberger, B. (Brigitte), Baumann, I. (Irith), Strahm, B. (Brigitte), Stary, J. (Jan), Locatelli, F. (Franco), Zecca, M. (Marco), Bergstraesser, E. (Eva), Dworzak, M.N. (Michael), Heuvel-Eibrink, M.M. (Marry) van den, Moerloose, B. (Barbara) de, Ogawa, S. (Susumu), Niemeyer, C.M. (Charlotte), Wlodarski, M. (Marcin), Hirabayashi, S. (Shinsuke), Flotho, C. (Christian), Moetter, J. (Jessica), Heuser, M. (Michael), Hasle, H. (Henrik), Gruhn, B. (Bernd), Klingebiel, T. (Thomas), Thol, F. (Felicitas), Schlegelberger, B. (Brigitte), Baumann, I. (Irith), Strahm, B. (Brigitte), Stary, J. (Jan), Locatelli, F. (Franco), Zecca, M. (Marco), Bergstraesser, E. (Eva), Dworzak, M.N. (Michael), Heuvel-Eibrink, M.M. (Marry) van den, Moerloose, B. (Barbara) de, Ogawa, S. (Susumu), Niemeyer, C.M. (Charlotte), and Wlodarski, M. (Marcin)

Abstract

Somatic mutations of the spliceosomal machinery occur frequently in adult patients with myelodysplastic syndrome (MDS). We resequenced SF3B1, U2AF35, and SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia. We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with systemic mastocytosis with MDS. In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that initially coexisted with an oncogenic NRAS mutation was absent at relapse, whereas the NRAS mutation persisted and a second, concomitant NRAS mutation later emerged. The patient with systemic mastocytosis and MDS carried both mutated U2AF35 and KIT in a single clone as confirmed by clonal sequencing. In the adult MDS patients sequenced for control purposes, we detected previously reported mutations in 7/30 and a novel SRSF2 deletion (c.284-307del) in 3 of 30 patients. These findings implicate that spliceosome mutations are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as driver mutations.

Published
2012
Full Text
View/download PDF

5. Complex karyotype newly defined: The strongest prognostic factor in advanced childhood myelodysplastic syndrome

Author

Göhring, G. (Gudrun), Michalova, K. (Kyra), Beverloo, H.B. (Berna), Betts, D. (David), Harbott, J. (Jochen), Haas, O.A. (Oskar), Kerndrup, G. (Gitte), Sainati, L. (Laura), Bergstraesser, E. (Eva), Hasle, H. (Henrik), Stary, J. (Jan), Trebo, M. (Monica), Heuvel-Eibrink, M.M. (Marry) van den, Zecca, M. (Marco), Wering, E.R. (Elisabeth) van, Fischer, A. (Alexandra), Noellke, P. (Peter), Strahm, B. (Brigitte), Locatelli, F. (Franco), Niemeyer, C.M. (Charlotte), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Michalova, K. (Kyra), Beverloo, H.B. (Berna), Betts, D. (David), Harbott, J. (Jochen), Haas, O.A. (Oskar), Kerndrup, G. (Gitte), Sainati, L. (Laura), Bergstraesser, E. (Eva), Hasle, H. (Henrik), Stary, J. (Jan), Trebo, M. (Monica), Heuvel-Eibrink, M.M. (Marry) van den, Zecca, M. (Marco), Wering, E.R. (Elisabeth) van, Fischer, A. (Alexandra), Noellke, P. (Peter), Strahm, B. (Brigitte), Locatelli, F. (Franco), Niemeyer, C.M. (Charlotte), and Schlegelberger, B. (Brigitte)

Abstract

To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity. Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall survival in patients with more than or equal to 3 clonal aberrations, which were not structurally complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results